KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Operating Leases (2018 - 2025)

Historic Operating Leases for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Q3 2025 value amounting to $26.4 million.

  • Amneal Pharmaceuticals' Operating Leases rose 74.4% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.4 million, marking a year-over-year increase of 74.4%. This contributed to the annual value of $24.8 million for FY2024, which is 4927.01% down from last year.
  • Amneal Pharmaceuticals' Operating Leases amounted to $26.4 million in Q3 2025, which was up 74.4% from $27.6 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Operating Leases' 5-year high stood at $64.0 million during Q4 2021, with a 5-year trough of $22.9 million in Q1 2025.
  • For the 5-year period, Amneal Pharmaceuticals' Operating Leases averaged around $32.7 million, with its median value being $28.3 million (2023).
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Operating Leases soared by 683.31% in 2022, and later plummeted by 4927.01% in 2024.
  • Over the past 5 years, Amneal Pharmaceuticals' Operating Leases (Quarter) stood at $64.0 million in 2021, then dropped by 7.45% to $59.2 million in 2022, then fell by 17.42% to $48.9 million in 2023, then tumbled by 49.27% to $24.8 million in 2024, then rose by 6.41% to $26.4 million in 2025.
  • Its Operating Leases stands at $26.4 million for Q3 2025, versus $27.6 million for Q2 2025 and $22.9 million for Q1 2025.